Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of MT-1303 in Moderate to Severe Crohn's Disease (Extension of MT-1303-E13)
2014-002557-19Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amiselimod in Crohn's disease, sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Long-term safety and tolerability of MT-1303. Started Sep 2014; status: completed.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-002557-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002557-19.